Skip to main content

Next generation HPC/QC in silico drug discovery platform for de novo design

Objective

ATLAS is a powerful in silico drug discovery platform leveraging the latest advances in high-performance and quantum computing. The platform is the result of decades of research by leading experts in molecular dynamics. The technology is grounded on over 100 peer-reviewed papers and two ERC grants. Our beta code has gathered important accolades like the prestigious ATOS-Joseph Fourier prize and first place at the foremost rational drug design competition—the SAMPL challenge.

ATLAS can replace costly and laborious experiments. It can even run entire drug discovery campaigns in silico, reducing cycle times and cost by at least 50%. By 2027, we will have a 35-project portfolio, and the first ATLAS-generated compound will reach the clinic. Thereafter, our objective is to generate a new candidate every 18 months. That year, our team will surpass 50 people and we’ll expand into the US market. We aim at securing a leadership position in the nascent in-silico drug discovery market.

Coordinator

QUBIT PHARMACEUTICALS
Net EU contribution
€ 2 500 000,00
Address
24 Rue Du Faubourg Saint-jacques
75014 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 2 500 000,00